Relmada Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.12.24	Relmada To Discontinue REL-1017 Reliance II And Relight Phase 3 Trials; Mulls Sale (RTTNews)
05.02.24	Biotech High-Flyers That Just Hit 52-Week Highs (RTTNews)
20.09.23	Relmada Therapeutics: Long-term Study With REL-1017 Shows Rapid, Sustained Therapeutic Effects (RTTNews)
14.06.23	RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD (PR Newswire)
03.06.23	ROSEN, A LEADING LAW FIRM, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - RLMD (PR Newswire)
12.12.22	Pre-market Movers: APVO, ACET, COUP, AMAM, CJJD… (RTTNews)
13.10.22	Relmada : Phase 3 Study Of REL-1017 In Major Depressive Disorder Fails To Meet Main Goal; Stock Down (RTTNews)
23.02.22	Relmada Announces Positive Results Of Study Evaluating REL-1017 Vs Ketamine For Abuse Potential (RTTNews)
09.12.21	AZN's Antibody Authorized For COVID-19, RDUS Shrinks, ZYME On Watch, FDA Panel Snubs RETA (RTTNews)
09.12.21	Relmada Prices Upsized Public Offering Of 8.82 Mln Shares At $17/shr (RTTNews)
04.10.21	FDA Confirms Relmada Not Required To Conduct Two-Year Carcinogenicity Study To Support REL-1017 Data (RTTNews)
10.08.21	Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results (PR Newswire)
05.08.21	Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021 (PR Newswire)
27.07.21	Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential (PR Newswire)
20.07.21	Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC (PR Newswire)
15.06.21	Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting (PR Newswire)
13.01.21	Will 2021 Continue To Be An Exciting Year For Relmada Therapeutics? (RTTNews)
28.04.20	Relmada Therapeutics (RLMD): Sending The Right Signals? (RTTNews)
17.12.19	Top Gainers: CLSD Making A Second Try, RLMD Abuzz, Busy Year Ahead For BTAI (RTTNews)
10.12.19	APTO On The Move, PLX To Effect Reverse Split, SCYX Plunges (RTTNews)
05.12.19	AUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims Workforce (RTTNews)
16.10.19	5 Top Gainers In Healthcare Sector (RETA, ABEO, CNST...) (RTTNews)
15.10.19	RETA Surges On Trial Data, RVNC On Track, All Eyes On RLMD Today (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Relmada Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten